#3529. Oral D-methionine protects against cisplatin-induced hearing loss in humans: phase 2 randomized clinical trial in India

October 2026publication date
Proposal available till 30-05-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Language and Linguistics;
Linguistics and Language;
Speech and Hearing;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2510 $1340 $1170 $1000 $
Contract №3529.1 Contract №3529.2 Contract №3529.3 Contract №3529.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
This exploratory Phase 2 clinical trial is the first determining safety and efficacy of oral D-methionine (D-met) in reducing cisplatin-induced ototoxicity. Randomised parallel double-blind placebo-controlled exploratory Phase 2 study. Fifty adult cancer patients received oral D-met or placebo before each cisplatin dose. Physical examination, blood collection and audiometry occurred at baseline and subsequent visits plus post-treatment audiometry. After attrition, final analysis included 27 patients. Side effects did not significantly differ between groups. Oral D-met reduces cisplatin-induced ototoxicity in humans.
Keywords:
cisplatin; D-methionine; efficacy; otoprotectant; ototoxicity; Phase 2 Clinical Trial

Contacts :
0